What type of study is this?

October 2, 2025Open Access

Clinical and Molecular Data to Predict Flares in DMARD optimization in Rheumatoid Arthritis: A Randomised, Controlled, Open-label, Non-inferiority Trial

View Full Paper

Ask AI

Bookmark

bDMARD dose optimization was found to be non-inferior to standard therapy regarding disease flare rates, supporting personalized treatment approaches.
The trial demonstrated a 39 flare occurrence rate with optimization at 22.7% and standard care at 17.2%, indicating safety profiles were similar.
In a phase IV trial analyzing 195 patients, two predictive models were developed to better understand flares and sustained remission in rheumatoid arthritis.
These predictive models, improved with molecular biomarkers, emphasize the importance of tailored therapies in managing rheumatoid arthritis effectively.

No takes yet. Share an insight, caveat, or question.

Randomized trial assessed disease flare rates in rheumatoid arthritis patients, suggesting bDMARD optimization is viable.

Blanco et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark